Major Research Findings

Ofatumumab (Kesimpta™) is a self-injectable anti-CD20 antibody that has been used in Germany since 2021 to treat relapsing multiple sclerosis (RMS). 1 This treatment provides a high degree of independence from intravenous forms of administration, making it a highly effective immunotherapy. 1

Multiple sclerosis (MS) is a chronic and disabling immune-mediated disease of the central nervous system (CNS) that primarily affects young adults. 2 MS imposes a significant economic burden on healthcare systems and society. 2 While the past 20 years have seen a continuous expansion of therapeutic options, there are still unmet needs in MS management. 2

Reasons for Side Effects

Anti-CD20 antibodies, like ofatumumab, target B cells and suppress the immune system, thereby reducing the symptoms of multiple sclerosis. 2 However, this immunosuppressive effect can increase the risk of infections. 2

Common Side Effects

Infections

Ofatumumab can increase the risk of infections due to its suppression of the immune system. 2

Injection Site Reactions

Self-injection of ofatumumab can cause reactions at the injection site. 1

Side Effects Management

Infections

To minimize the risk of infections, regular health checks and prompt consultation with a doctor if any symptoms appear are crucial. 2

Injection Site Reactions

To mitigate injection site reactions, learning the proper injection technique as instructed by your doctor is essential. 1

Comparison between Studies

Similarities between Studies

Both studies suggest that ofatumumab may be effective in treating relapsing multiple sclerosis. 1 2

Differences between Studies

One study focuses on the patient experience with self-injection of ofatumumab. 1 The other study is a review of various medications, including ofatumumab, for the treatment of multiple sclerosis. 2

Real-Life Application Considerations

While ofatumumab has the potential to be effective in treating relapsing multiple sclerosis, its immunosuppressive effects can increase the risk of infections. 2

Self-injection of ofatumumab offers a more independent treatment method for patients, but it is crucial to learn the proper injection technique. 1

Current Research Limitations

The long-term effects of ofatumumab are not yet fully understood. 2

Future Research Directions

Further research is necessary to understand the long-term effects and safety of ofatumumab. 2

Conclusion

Ofatumumab holds potential as a treatment for relapsing multiple sclerosis, but it carries the risk of increased infections due to its immunosuppressive nature. 2 Self-injection of ofatumumab offers greater independence for patients, but proper injection technique is essential. 1

When considering the use of ofatumumab, it is important to discuss the risks of infections and side effects with your doctor. 2